Premedication is a cornerstone of safe anesthetic practice. The drugs chosen for premedication fundamentally influence the entire anesthetic event, from induction smoothness to recovery quality.
Overview and Clinical Importance
Premedication is a cornerstone of safe anesthetic practice. The drugs chosen for premedication fundamentally influence the entire anesthetic event, from induction smoothness to recovery quality. Understanding the pharmacology, clinical effects, and appropriate selection of premedicant agents is essential for entry-level veterinary competency and is heavily tested on the BCSE.
The BCSE tests your ability to select appropriate premedicant combinations based on patient status (ASA classification), species, and procedure type. Questions often present clinical scenarios requiring you to identify contraindications, predict adverse effects, or select optimal drug combinations.
High-YieldDomain 5 (Anesthesia) comprises 20-23 questions. Premedication concepts are integrated throughout this domain, connecting pharmacology, physiology, and clinical decision-making.
| Primary Aims |
Clinical Benefit |
| Sedation and anxiolysis |
Reduces stress, facilitates handling, decreases catecholamine release |
| Preventive analgesia |
Blocks pain pathways before surgical stimulus, reduces wind-up phenomenon |
| Reduce induction agent dose |
Smoother induction, fewer cardiovascular effects from induction drugs |
| Reduce maintenance requirements |
Lower MAC of inhalants, fewer cardiovascular effects |
| Smooth recovery |
Gradual emergence, reduced dysphoria, continued analgesia |
| Prevent drug side effects |
Example: anticholinergics to prevent opioid-induced bradycardia |
| Effect |
Clinical Significance |
| Sedation |
Dose-dependent; enhanced when combined with opioids (neuroleptanalgesia); cannot be reversed |
| Hypotension |
Alpha-1 blockade causes vasodilation; reduction in cardiac index also contributes; NOT due to decreased SVR alone |
| Splenic sequestration |
Red blood cells pool in spleen, reducing PCV by 20-30 percent; avoid in anemic patients |
| Antiemetic |
Dopamine antagonism in CRTZ; reduces opioid-induced vomiting |
| Seizure threshold |
May lower seizure threshold; historically contraindicated in epileptics (debated) |
| Duration |
Long-acting (4-6 hours); recovery may be prolonged |
Aims of Premedication
Understanding the goals of premedication helps guide rational drug selection. A balanced premedication protocol typically combines a sedative with an analgesic to achieve multiple objectives synergistically.
MEMORY AID - SAFE PREMED: S = Sedation and anxiolysis, A = Analgesia (preventive), F = Facilitate induction (reduce dose), E = Ensure smooth recovery, P = Prevent side effects of other drugs, R = Reduce maintenance requirements, E = Enhance patient safety, M = Minimize stress response, E = Ease handling, D = Decrease secretions (when needed)
[Include Image: Figure 1. Sedation levels in dogs showing different stages from light to deep sedation]
| Species |
Dose Range |
Notes |
| Dogs |
0.01-0.05 mg/kg IM, IV |
Lower doses (0.01-0.02) for sedation; ceiling effect above 0.1 mg/kg |
| Cats |
0.01-0.05 mg/kg IM, IV |
Often combined with opioid for enhanced sedation |
| Horses |
0.02-0.1 mg/kg IV, IM |
Penile prolapse risk in stallions; priapism reported |
| Phase |
Mechanism |
Clinical Effect |
| Phase 1 (Early) |
Peripheral alpha-2B receptor activation on blood vessels |
Vasoconstriction leads to HYPERTENSION and REFLEX BRADYCARDIA |
| Phase 2 (Later) |
Central sympatholytic effect predominates |
HYPOTENSION and BRADYCARDIA (sympatholytic) |
Phenothiazines: Acepromazine
Mechanism of Action
Acepromazine (ACP) is a phenothiazine derivative that produces sedation through dopamine D2 receptor antagonism in the CNS. It also blocks alpha-1 adrenergic receptors peripherally, leading to vasodilation and potential hypotension. Additionally, ACP has antihistaminic (H1) and weak anticholinergic properties.
MEMORY AID - ACE the DAH: Acepromazine blocks D = Dopamine (CNS sedation), A = Alpha-1 (vasodilation, hypotension), H = Histamine (antiemetic effect)
Clinical Effects
High-YieldAcepromazine reduces hemoglobin concentration via splenic sequestration, decreasing oxygen delivery. It is contraindicated in patients with anemia or hypovolemia.
Dosing and Administration
High-YieldNEVER use acepromazine in: (1) Hypovolemic or shock patients, (2) Anemic patients, (3) Patients with known seizure disorders (controversial), (4) Boxers and giant breeds (idiosyncratic reactions reported), (5) Stallions (penile prolapse risk).
MEMORY AID - ACP Contraindications - SHABS: S = Shock/hypovolemia, H = History of seizures, A = Anemia, B = Boxers/Brachycephalics (controversial), S = Stallions (penile prolapse)
Key Points for BCSE
- No reversal agent exists for acepromazine - effects must wear off naturally
- Acepromazine has NO analgesic properties - always combine with an opioid for painful procedures
- Reduces propofol induction dose and inhalant MAC requirements
- Hypotension worsens under general anesthesia with inhalants (decreased SVR)
[Include Image: Figure 2. Dopamine receptor signaling pathway showing D2 receptor antagonism]
| Property |
Dexmedetomidine |
Xylazine |
| Alpha-2 selectivity |
Highly selective (1620:1 ratio alpha-2 to alpha-1) |
Less selective (160:1 ratio) |
| Primary use |
Dogs and cats; becoming standard of care |
Large animals (horses, cattle); less common in small animals |
| Sedation quality |
Profound, reliable sedation |
Good sedation but higher mortality risk in small animals |
| Analgesia duration |
Longer analgesic effect |
Relatively short analgesia (15-30 min) |
| Vomiting |
Common in dogs and cats (central alpha-2 effect) |
Common especially in cats |
| Reversal |
Atipamezole |
Atipamezole or yohimbine |
| Ruminant caution |
Use with caution - pulmonary edema risk |
Higher risk of pulmonary edema and hypoxemia |
| Drug |
Receptor Activity |
Clinical Notes |
| Atipamezole (Antisedan) |
Selective alpha-2 antagonist |
Drug of choice; give IM at same volume as dexmedetomidine given; reverses sedation and analgesia |
| Yohimbine |
Alpha-2 antagonist (less selective) |
Used in large animals; may be used for xylazine reversal |
Alpha-2 Adrenergic Agonists
Mechanism of Action
Alpha-2 agonists bind to alpha-2 adrenergic receptors (G-protein coupled, Gi subtype) in both the CNS and periphery. Central effects include sedation (locus coeruleus), analgesia (spinal cord dorsal horn), and decreased sympathetic outflow. Peripheral effects include vasoconstriction (alpha-2B on blood vessels), decreased insulin release (hyperglycemia), and decreased GI motility.
MEMORY AID - Alpha-2 Sites and Effects - SAVA: S = Sedation (locus coeruleus), A = Analgesia (spinal cord), V = Vasoconstriction (peripheral), A = Anti-sympathetic (decreased NE release)
Cardiovascular Effects - Biphasic Response
Alpha-2 agonists produce a characteristic biphasic cardiovascular response:
High-YieldDuring Phase 1 hypertension, DO NOT treat bradycardia with anticholinergics! The resulting tachycardia against high afterload dramatically increases myocardial oxygen demand and can cause cardiac complications.
MEMORY AID - Biphasic Response - First HIGH then LOW: First: Hypertension + bradycardia (peripheral vasoconstriction); Then: Hypotension + bradycardia (central sympatholysis). Remember: High blood pressure BEFORE low blood pressure.
Drug Comparison: Dexmedetomidine vs. Xylazine
High-YieldXylazine is associated with HIGHER MORTALITY in dogs and cats compared to other premedicants. Dexmedetomidine is preferred when an alpha-2 agonist is needed in small animals.
Other Important Effects
- Vomiting: Common in cats and dogs due to central alpha-2 activation - may be beneficial before surgery
- Hyperglycemia: Decreased insulin release from pancreatic beta cells
- Diuresis: Decreased ADH release and/or antagonism of ADH effects on collecting ducts
- Decreased GI motility: Important consideration in horses (colic risk) and ruminants
- Hypothermia: Depression of thermoregulatory center
MEMORY AID - Alpha-2 Side Effects - VHD-GI-H: V = Vomiting, H = Hyperglycemia, D = Diuresis, GI = GI hypomotility, H = Hypothermia
Reversal Agents
High-YieldWhen reversing alpha-2 agonists, remember that analgesia is also reversed. Ensure alternative analgesia is provided if the patient has ongoing pain.
MEMORY AID - Atipamezole Dosing Rule: For dexmedetomidine: Give Atipamezole at the SAME VOLUME as the dexmedetomidine dose that was given. Example: 0.2 mL dexmedetomidine given IM = 0.2 mL atipamezole IM.
[Include Image: Figure 3. Alpha-2 adrenergic receptor signaling pathway showing Gi protein-coupled mechanism]
| Effect |
Clinical Significance |
| Anxiolysis |
Primary therapeutic effect; reduces fear and anxiety without deep sedation |
| Muscle relaxation |
Centrally mediated; useful to prevent ketamine-induced muscle rigidity |
| Anticonvulsant |
Increases seizure threshold; diazepam is first-line for status epilepticus |
| Minimal sedation in healthy animals |
Excitement and disinhibition common in healthy dogs and cats when given alone |
| Cardiovascular stability |
Minimal effects on heart rate, blood pressure, or cardiac output - major advantage |
| No analgesia |
Benzodiazepines provide NO pain relief; always combine with opioid if analgesia needed |
| Property |
Diazepam (Valium) |
Midazolam (Versed) |
| Water solubility |
NOT water soluble; dissolved in propylene glycol |
Water soluble at pH less than 4; becomes lipid soluble at body pH |
| IM administration |
Painful and erratic absorption; NOT recommended IM |
Well absorbed IM; no pain on injection |
| Potency |
Standard reference |
2-3 times more potent than diazepam |
| Onset |
Moderate onset |
Faster onset than diazepam |
| Plastic binding |
Binds to plastic IV tubing and syringes |
Does not bind to plastic |
| Storage |
Light sensitive; store in dark container |
More stable |
Benzodiazepines
Mechanism of Action
Benzodiazepines enhance the effect of GABA at GABA-A receptors by increasing the frequency of chloride channel opening. This results in hyperpolarization of neurons and CNS depression. Unlike barbiturates, benzodiazepines modulate (not directly activate) GABA-A receptors, contributing to their wide safety margin.
MEMORY AID - Benzos and Barbiturates - Frequency vs Duration: Benzodiazepines increase FREQUENCY of chloride channel opening; Barbiturates increase DURATION of chloride channel opening. Remember: Benzos = FREQUENTly open; Barbs = DURATION open.
Clinical Effects
High-YieldBenzodiazepines provide NO ANALGESIA and often cause PARADOXICAL EXCITEMENT in healthy, young animals when used alone. Reserve for sick patients (ASA III-V) or combine with other agents.
Diazepam vs. Midazolam Comparison
MEMORY AID - Why MIDAZOLAM is Better for IM - MIDAZ: M = More potent, I = IM injection is painless, D = Does not bind plastic, A = Absorption is reliable, Z = Zero propylene glycol (water soluble)
Clinical Applications
- ASA III-V patients: Excellent choice due to cardiovascular stability; provides anxiolysis without cardiovascular depression
- Co-induction with ketamine: Prevents muscle rigidity and excitation associated with ketamine; provides muscle relaxation
- Fentanyl-midazolam combinations: IV protocol for high-risk patients; provides sedation with minimal cardiovascular effects
- Seizure management: Diazepam is first-line for status epilepticus; can be given IV or per rectum
High-YieldCombining midazolam with medetomidine in dogs can cause a HIGH INCIDENCE OF EXCITEMENT. This combination should be avoided.
Reversal Agent: Flumazenil
Flumazenil is a competitive antagonist at the GABA-A benzodiazepine binding site. It reverses sedation, anxiolysis, and muscle relaxation caused by benzodiazepines. Flumazenil is expensive and not widely available in veterinary practice, limiting its routine use. Duration of action may be shorter than the benzodiazepine being reversed, so re-sedation is possible.
MEMORY AID - Reversal Agents - FAAN: F = Flumazenil reverses benzodiazepines, A = Atipamezole reverses alpha-2 agonists, A = Atropine treats bradycardia (anticholinergic), N = Naloxone reverses opioids
[Include Image: Figure 4. GABA-A receptor showing benzodiazepine binding site and chloride channel]
| Receptor |
Effects When Activated |
Clinical Significance |
| Mu (μ) |
Supraspinal analgesia; euphoria; respiratory depression; bradycardia; decreased GI motility; miosis (dogs) or mydriasis (cats); physical dependence |
Primary target for analgesia; full mu agonists provide best pain relief |
| Kappa (?) |
Spinal analgesia; sedation; miosis; minimal respiratory depression |
Butorphanol acts here; ceiling effect for analgesia |
| Delta (?) |
Modulates mu receptor activity; spinal analgesia |
Less clinically relevant in veterinary medicine |
| Classification |
Examples |
Clinical Notes |
| Full Mu Agonists |
Morphine, hydromorphone, fentanyl, methadone, oxymorphone |
Best analgesia; dose-dependent effects; no ceiling for analgesia (but respiratory depression increases with dose) |
| Partial Mu Agonist |
Buprenorphine |
High receptor affinity but partial activation; ceiling effect; slow onset (30-45 min); long duration; difficult to reverse with naloxone |
| Mixed Agonist-Antagonist |
Butorphanol |
Kappa agonist and mu antagonist; good sedation; mild-moderate analgesia with ceiling effect; short duration (1-2 hours) |
| Pure Antagonists |
Naloxone, naltrexone |
Competitive antagonist at all opioid receptors; reverses analgesia, sedation, and respiratory depression |
Opioids for Premedication
Mechanism of Action
Opioids bind to opioid receptors (mu, kappa, delta) in the brain, spinal cord, and peripheral tissues. Activation of these G-protein coupled receptors leads to inhibition of adenylyl cyclase, increased potassium conductance, and decreased calcium influx, resulting in reduced neuronal excitability and neurotransmitter release.
Opioid Receptor Types
MEMORY AID - Mu Receptor Effects - SUPER: S = Supraspinal analgesia, U = Urinary retention, P = Pupil changes (miosis dogs/mydriasis cats), E = Euphoria, R = Respiratory depression
Opioid Classification by Receptor Activity
High-YieldFor patients with preoperative PAIN, choose methadone or another full mu agonist over butorphanol. Butorphanol has a ceiling effect for analgesia and is better for sedation than pain control.
MEMORY AID - Opioid Selection for Pain vs Sedation: PAINFUL patient = Full MU agonist (Methadone, Morphine, Hydromorphone); SEDATION needed = Butorphanol works well (but limited analgesia)
Commonly Used Opioids for Premedication
MEMORY AID - Opioid Vomiting Risk - MHB: M = Morphine (High vomiting); H = Hydromorphone (Moderate); B = Butorphanol (Low - often used as antiemetic)
Cardiovascular and Respiratory Effects
Opioids have limited cardiovascular effects at clinical doses, making them excellent for high-risk patients. Bradycardia may occur due to vagal stimulation but is usually not associated with hypotension in healthy patients. Respiratory depression is dose-dependent and more significant with full mu agonists. Panting is common in dogs.
High-YieldOpioids produce SYNERGISTIC sedation when combined with sedatives (acepromazine or alpha-2 agonists). This allows lower doses of each drug to be used, reducing side effects.
Reversal: Naloxone
Naloxone is a pure competitive antagonist at all opioid receptors. It reverses sedation, analgesia, and respiratory depression. Dose: 0.01-0.04 mg/kg IV (dogs and cats). Duration is shorter than most opioids, so re-sedation may occur. Titrate to effect to avoid complete reversal of analgesia when possible.
[Include Image: Figure 5. Opioid receptor types and their signaling pathways]
| Drug |
Class |
Duration |
Key Features |
| Morphine |
Full mu agonist |
3-4 hours |
High vomiting incidence; histamine release if given IV rapidly; gold standard for pain |
| Hydromorphone |
Full mu agonist |
3-4 hours |
5x more potent than morphine; less vomiting; hyperthermia in cats; commonly used in small animals |
| Methadone |
Full mu agonist (also NMDA antagonist) |
4-6 hours |
Less vomiting; NMDA antagonism provides additional analgesia; good for chronic pain |
| Fentanyl |
Full mu agonist |
20-30 min (bolus) |
Highly potent (100x morphine); rapid onset; short duration; often used IV or as CRI |
| Butorphanol |
Kappa agonist, mu antagonist |
1-2 hours |
Good sedation; mild visceral analgesia; ceiling effect; short duration; commonly combined with sedatives |
| Buprenorphine |
Partial mu agonist |
6-12 hours |
Long duration; slow onset; high receptor affinity makes reversal difficult; good for cats |
| Effect |
Clinical Significance |
| Increased heart rate |
Primary therapeutic use; prevents and treats bradycardia from vagal stimulation or drugs |
| Decreased salivation |
Reduces airway secretions; was more important with older anesthetics (ether) |
| Decreased GI motility |
Can worsen or contribute to ileus; problematic in horses and ruminants |
| Mydriasis |
Pupil dilation; contraindicated in glaucoma patients |
| Bronchodilation |
Minor effect; may be beneficial in patients with bronchospasm |
| Decreased bronchial secretions |
Thickens secretions, potentially making them harder to clear |
Anticholinergics
Mechanism of Action
Anticholinergics (also called antimuscarinics or parasympatholytics) competitively antagonize acetylcholine at muscarinic receptors in the parasympathetic nervous system. Both atropine and glycopyrrolate are relatively non-selective for muscarinic receptor subtypes (M1-M5).
MEMORY AID - Anticholinergic = Anti-SLUD-B: Anticholinergics BLOCK the SLUD effects of parasympathetic activation: S = Salivation decreased, L = Lacrimation decreased, U = Urination decreased, D = Defecation decreased, B = Bradycardia prevented
Clinical Effects
High-YieldROUTINE premedication with anticholinergics is NO LONGER RECOMMENDED. Modern inhalants have minimal parasympathetic effects. Reserve anticholinergics for specific indications.
Atropine vs. Glycopyrrolate Comparison
MEMORY AID - Atropine vs Glycopyrrolate - AG Comparison: A = Atropine: Acts fast, Arrhythmogenic, Accesses brain; G = Glycopyrrolate: Gradual onset, Gentle on heart, Cannot Get into brain (quaternary amine)
Indications for Anticholinergics
Contraindications and Cautions
High-YieldCRITICAL: DO NOT give anticholinergics with alpha-2 agonists during the hypertensive phase! The combination of increased HR (anticholinergic) and high afterload (alpha-2 vasoconstriction) dramatically increases myocardial oxygen demand and can cause life-threatening hypertension and arrhythmias.
- Tachycardia: Patients with pre-existing tachycardia, hypertrophic cardiomyopathy, or restrictive cardiomyopathy
- GI stasis: May worsen ileus; use with caution in horses and ruminants
- Glaucoma: Mydriasis increases intraocular pressure
- Concurrent alpha-2 agonist use: Risk of severe hypertension and ventricular arrhythmias
MEMORY AID - Anticholinergic Contraindications - THAG: T = Tachycardia (pre-existing), H = Hypertrophic cardiomyopathy, A = Alpha-2 agonist concurrent use, G = GI stasis/Glaucoma
Dosing
MEMORY AID - Species Note - Rabbits and Atropine: Rabbits (and some rodents) have ATROPINASE enzyme in their liver. Higher doses of atropine are needed, or use glycopyrrolate instead.
[Include Image: Figure 6. Muscarinic receptor showing acetylcholine binding and competitive antagonism by atropine]
| Property |
Atropine |
Glycopyrrolate |
| Onset of action |
Rapid (1-2 minutes IV) |
Slower (2-3 minutes IV) |
| Duration |
60-90 minutes |
2-4 hours |
| CNS penetration |
YES - crosses blood-brain barrier (tertiary amine) |
NO - does not cross BBB (quaternary amine) |
| Placental crossing |
YES - crosses placenta |
NO - does not cross placenta |
| Tachycardia |
More pronounced tachycardia; more arrhythmogenic |
Less likely to cause severe tachycardia; preferred in cardiac patients |
| Initial bradycardia |
Less common |
May see transient AV block before HR increases |
| Cost |
Less expensive |
More expensive |
| Emergency use |
Drug of choice due to rapid onset |
Not ideal for emergencies due to slower onset |
| Indication |
Rationale |
| Neonates and pediatrics (less than 3-4 months) |
Cardiac output is heart rate dependent; cannot tolerate bradycardia |
| Pre-existing bradycardia (conduction disturbances) |
Patients with AV block or high vagal tone |
| High-dose opioid protocols |
Prevents vagally-mediated bradycardia |
| Procedures with vagal stimulation risk |
Oculocardiac reflex; visceral manipulation |
| Treatment of intraoperative bradycardia |
Emergency use when bradycardia is symptomatic |
| Reversal of neuromuscular blockade |
Given with anticholinesterases to prevent muscarinic side effects |
Premedication Protocols by ASA Status
Drug selection should be based on patient health status (ASA classification), species, procedure type, and anticipated pain level. The following table provides general guidance for protocol selection:
High-YieldThe key principle: Match drug selection to patient status. Sicker patients need drugs with fewer cardiovascular effects. When in doubt, opioids provide analgesia with minimal cardiovascular depression.
MEMORY AID - ASA Status Drug Selection - S.A.F.E.: S = Sick patients need Simple protocols (opioid-based), A = Acepromazine/Alpha-2 agonists for healthy patients, F = Fentanyl-midazolam for high-risk patients, E = Evaluate each patient individually
| Drug |
Preanesthetic Dose |
Emergency Dose |
| Atropine |
0.02-0.04 mg/kg IM, SQ |
0.04 mg/kg IV (dogs and cats) |
| Glycopyrrolate |
0.005-0.01 mg/kg IM, SQ |
0.01 mg/kg IV |
| ASA Status |
Recommended Protocols |
Rationale and Notes |
| ASA I-II (Healthy) |
Acepromazine + opioid OR Dexmedetomidine + opioid |
Reliable sedation and analgesia; cardiovascular effects manageable in healthy patients |
| ASA III (Moderate disease) |
Low-dose acepromazine + opioid OR Opioid alone (if sufficient sedation) |
Reduce doses to minimize cardiovascular depression; assess individual patient risk |
| ASA IV-V (Severe disease) |
Opioid alone OR Opioid + midazolam (fentanyl-midazolam IV) |
Minimize cardiovascular depression; benzodiazepines provide anxiolysis with cardiovascular stability |
| Cardiac patients |
Opioid +/- low-dose benzodiazepine; AVOID alpha-2 agonists and acepromazine |
Opioids have minimal cardiac effects; avoid drugs causing hypotension or bradycardia |
| Pediatric (less than 3 months) |
Opioid + benzodiazepine + anticholinergic |
HR-dependent cardiac output; anticholinergic prevents bradycardia |